CEO Total Pay
$212K
FY2024 Summary Compensation, below median
ADVM FY2024 SEC EDGAR DEF 14A
Adverum Biotechnologies, Inc. CEO pay ratio
The CEO earned $212K in FY2024 against median worker pay of $212,303 · Chemicals & Pharmaceuticals.
- State
- DE
- Filing date
- 2025-04-28
- Industry
- Chemicals & Pharmaceuticals
- Fiscal year
- FY2024
Data updated August 2026
Subscribe to Adverum Biotechnologies, Inc. CEO pay filing updates (RSS)
CEO-to-worker pay ratio
19:1
Below Average (Scale: 0–1000:1)
CEO pay
$212K
Median worker
$212,303
Latest filing FY2024. This company's newest DEF 14A on file is for FY2024, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Adverum Biotechnologies, Inc. reported a 19:1 CEO-to-worker pay ratio in FY2024 - at or below the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
- Pay ratio
- 19:1
- FY2024 disclosed
- CEO total
- $212K
- Summary Compensation Table total
- Median worker
- $212,303
- Dodd-Frank median employee
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
CEO Compensation Breakdown, FY2024
A component-level pay breakdown is not reported in Adverum Biotechnologies, Inc.'s structured SEC pay-ratio disclosure. See our methodology →
Filing-year trail · Adverum Biotechnologies, Inc.
Complete DEF 14A pay-ratio filings for this CIK across FY2021–2024. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).
- Latest ratio
- 19:1
- FY2024
- vs prior FY
- +12:1
- from FY2023 7:1
- CEO $ YoY
- -7.5%
- $212K latest
- Filings shown
- 4
- FY2021–2024
| FY | CEO pay | Δ pay | Median worker | Pay ratio | Δ ratio |
|---|---|---|---|---|---|
| 2021 | $188K | - | $188,229 | 48:1 | - |
| 2022 | $170K | -9.9% | $169,590 | 17:1 | -31:1 |
| 2023 | $229K | +35% | $229,443 | 7:1 | -10:1 |
| 2024 | $212K | -7.5% | $212,303 | 19:1 | +12:1 |
Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1501756, FY2021–2024. Adjacent-year deltas only.
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
19:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$212K
Companies in Industry
168
vs. Industry Median
Below
Adverum Biotechnologies, Inc.: near-parity Item 402(u) ratio
Adverum Biotechnologies, Inc. stamps FLOOR · ELITE-MED at 19:1 against $212,303 median worker pay in FY2024. the CEO earned 19× the median employee ($212,303) in FY2024.
At $212,303 median worker pay, the FLOOR stamp is near pay-parity territory under MICRO CEO total.
Pay Ratio
19:1
Below typical
What FY2024 shows for Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc. stamps FLOOR · ELITE-MED at 19:1 against $212,303 median worker pay in FY2024. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Adverum Biotechnologies, Inc.'s $212K CEO total is at or below the $7.9M industry median CEO pay.
Adverum Biotechnologies, Inc. stamps FLOOR · MICRO · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Key Data, FY2024
- Total Compensation
- $212K
- Median Employee Pay
- $212,303
- Pay Ratio
- 19:1
- Filing Date
- 2025-04-28
Company Info
- Ticker
- ADVM
- CIK
- 1501756
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2836
- State
- DE
SEC EDGAR DEF 14A for CIK 1501756, FY2024. Informational only, not investment advice. Verify on EDGAR.
Read our methodology - how this data is sourced, computed, and verified. Adverum Biotechnologies, Inc. stamps FLOOR · ELITE-MED at 19:1 against $212,303 median worker pay in FY2024.
Read with Adverum Biotechnologies, Inc.
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · MICRO · ELITE-MED.
APA Corp · MICRO
ABS(ceo_total_comp) peer at $208K (Δ $4K lighter vs Adverum Biotechnologies, Inc.); MODEST · ELITE-MED vs this page's FLOOR · MICRO · ELITE-MED.
iRhythm Holdings, Inc. · MICRO
ABS(ceo_total_comp) peer at $217K (Δ $4K heavier vs Adverum Biotechnologies, Inc.); FLOOR · HIGH-MED vs this page's FLOOR · MICRO · ELITE-MED.
Lantheus Holdings, Inc. · MICRO
ABS(ceo_total_comp) peer at $203K (Δ $9K lighter vs Adverum Biotechnologies, Inc.); MODEST · ELITE-MED vs this page's FLOOR · MICRO · ELITE-MED.
Verisign Inc/ca · MICRO
ABS(ceo_total_comp) peer at $222K (Δ $10K heavier vs Adverum Biotechnologies, Inc.); MODEST · ELITE-MED vs this page's FLOOR · MICRO · ELITE-MED.
Chemicals & Pharmaceuticals benchmark
Adverum Biotechnologies, Inc. stamps FLOOR · MICRO · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
Pay-ratio rankings · FLOOR
See where FLOOR · MICRO packages sit on the national leaderboard after reading Adverum Biotechnologies, Inc..
Ratio primer · FLOOR
Adverum Biotechnologies, Inc.'s FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Adverum Biotechnologies, Inc. (CIK 1501756), FY2024. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.